Kristina Lohmann

Wiesbaden, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Reduction of impairment of sexual activity in patients with genital psoriasis treated with risankizumab: interim results of a real-world study.

Reduction of impairment of sexual activity in patients with genital psoriasis treated with risankizumab: interim results of a real-world study.

Journal: The Journal of dermatological treatment

Published: November 27, 2025

Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.

Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.

Journal: Dermatology and therapy

Published: October 01, 2025

Prevalence of Genital Psoriasis and Its Impact on Patients' Sexual Life in Routine Care: Epidemiologic Survey in Germany.

Prevalence of Genital Psoriasis and Its Impact on Patients' Sexual Life in Routine Care: Epidemiologic Survey in Germany.

Journal: Psoriasis (Auckland, N.Z.)

Published: January 10, 2025

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).

Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).

Journal: Viruses

Published: May 03, 2022

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).

Journal: Journal of viral hepatitis

Published: April 08, 2021

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal.

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal.

Journal: Health science reports

Published: November 18, 2020

Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.

Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: November 13, 2020

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.

Journal: Advances in therapy

Published: September 11, 2020

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: June 15, 2020

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.

Journal: Advances in therapy

Published: June 12, 2020

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.

Journal: Alimentary pharmacology & therapeutics

Published: December 19, 2018

Knowledge and training needs of nurses and physicians on unsuitable drugs for patients with dysphagia or feeding tubes.

Knowledge and training needs of nurses and physicians on unsuitable drugs for patients with dysphagia or feeding tubes.

Journal: Journal of clinical nursing

Published: May 06, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026